Phase I/II Trial of OSI-906 in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Ductal Adenocarcinoma of the Pancreas
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 试验地点
- 2
- 主要终点
- Number of patients with adverse events as a measure of safety and tolerability
研究概览
简要总结
OSI-906 is a new drug that may stop cancer cells from growing abnormally. This drug has been used in other research studies and information from those suggests that OSI-906 may help block cell receptors involved in tumor growth.
Gemcitabine and erlotinib are used as standard treatment for pancreatic cancer. In this research study, the investigators are looking for the highest dose of OSI-906 that can be given safely in combination with gemcitabine and erlotinib. This dose will then be given together with gemcitabine and erlotinib to a further group of patients with pancreatic cancer.
详细描述
This study will be conducted in two parts: a phase I study and a phase II study. In both instances, a treatment cycle is 28 days (4 weeks). Subjects will take OSI-906 by mouth, twice a day, every day. Subjects will receive gemcitabine through an IV in clinic over 30 minutes on days 1, 8 and 15 of each 28-day cycle. Subjects will take erlotinib by mouth, once a day, every day.
At every visit subjects will have a physical exam and blood tests. An EKG will be done on days 1, 8 and 15 of cycle 1 and on day 1 of all subsequent cycles. A CT scan will be done every 2 cycles (8 weeks).
Subjects will complete a daily drug diary and perform glucose monitoring (finger stick) once daily at home.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Metastatic pancreatic ductal adenocarcinoma
- •Measurable disease
- •Life expectancy > 12 weeks
- •Normal organ and marrow function
- •Fasting blood glucose </= 150 mg/dL
- •Able to swallow pills
排除标准
- •Prior chemotherapy or radiotherapy for treatment of pancreatic cancer
- •Receiving any other experimental agent
- •Known brain metastases
- •History of allergic reaction attributed to compounds of similar chemical or biologic composition to gemcitabine, erlotinib, or OSI-906
- •Impairment of gastrointestinal function or gastrointestinal disease (e.g., ulcerative disease, uncontrolled nausea, vomiting, or diarrhea)
- •Use of enzyme-inducing anti-epileptic drugs
- •Diabetes mellitus which requires the use of exogenous insulin for glucose control
- •Major surgery within 4 weeks of the start of study treatment
- •Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- •Use of strong or moderate CYP1A2 inhibitors/inducers
- •Pregnant or breast feeding
- •History of a different malignancy unless disease-free for at least 3 years
- •HIV positive
研究组 & 干预措施
Gemcitabine, Erlotinib, OSI-906
Experimental treatment arm
干预措施: Gemcitabine, Erlotinib, OSI-906 (Drug)
Gemcitabine, Erlotinib
Standard treatment arm
干预措施: Gemcitabine, Erlotinib (Drug)
结局指标
主要结局
Number of patients with adverse events as a measure of safety and tolerability
时间窗: 1 years
Phase I study to assess the safety, tolerability and maximally tolerated dose (MTD) of OSI-906 administered in combination with gemcitabine and erlotinib is patients with metastatic pancreatic ductal adenocarcinoma
Survival among patients receiving gemcitabine + erlotinib versus gemcitabine + erlotinib + OSI-906
时间窗: 2 years
Phase II trial to assess overall survival associated with OSI-906, gemcitabine and erlotinib compared with gemcitabine and erlotinib alone in patients with previous untreated metastatic pancreatic ductal adenocarcinoma
次要结局
- Progression-free survival among patients receiving gemcitabine + erlotinib vs. gemcitabine + erlotinib + OSI-906(2 years)
- Tumor response rate among patients receiving gemcitabine + erlotinib versus gemcitabine + erlotinib + OSI-906(2 years)
研究者
Brian Wolpin, MD, MPH
Overall PI
Dana-Farber Cancer Institute